Search

Your search keyword '"Grever, Michael R,"' showing total 1,139 results

Search Constraints

Start Over You searched for: Author "Grever, Michael R," Remove constraint Author: "Grever, Michael R,"
1,139 results on '"Grever, Michael R,"'

Search Results

7. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

9. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

10. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

12. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

25. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

26. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

27. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

28. Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

29. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

30. Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

31. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

32. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib

37. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.

40. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

43. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

45. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

48. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

49. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Catalog

Books, media, physical & digital resources